Extrawell Pharmaceutical Holdings Limited disclosed on 21 October 2026 that its Board has approved the grant of 92.00 million share options under the 2022 Share Option Scheme. The options cover three executive directors—Dr. Xie Yi, Ms. Wong Sau Kuen and Mr. Wu Xiangyun—and long-serving chief scientific adviser Dr. Mao Yumin.

Key terms • Aggregate options: 92.00 million, representing 3.17% of the company’s issued share capital. • Exercise price: HK$0.0726 per share, matching the higher of (i) same-day closing price (HK$0.056), (ii) five-day average closing price (HK$0.0726) and (iii) the nominal share value (HK$0.01). • Vesting: 12 months from grant date (20 October 2027). • Exercise window: 21 October 2026 to 20 October 2036. • Consideration: HK$1.00 payable by each grantee upon acceptance.

Distribution of options • Dr. Xie Yi (Executive Director & Chairman): 23.00 million (0.79% of shares). • Ms. Wong Sau Kuen (Executive Director & Company Secretary): 23.00 million (0.79%). • Mr. Wu Xiangyun (Executive Director): 23.00 million (0.79%); subject to individual performance targets. • Dr. Mao Yumin (Chief Scientific Adviser): 23.00 million (0.79%).

Governance and compliance • Each relevant director abstained from voting on his or her own option grant. • Dr. Mao, holding a 6.55% equity stake and formerly a director of a non-wholly owned subsidiary, is classified as a connected person at the subsidiary level under Rule 14A.07(2). As all percentage ratios are below 1%, the transaction is exempt from circular and independent shareholders’ approval requirements under Rule 14A.76(1)(b). • Clawback provisions apply in cases of misconduct, insolvency or contract breaches, consistent with scheme rules. • No financial assistance has been provided by the Group for the subscription of shares.

Scheme capacity Following the proposed grants and assuming full acceptance, 70.50 million shares remain available for future option awards under the 2022 Share Option Scheme.